The Turnaround Letter. Click Here for 30 Day Free Trial
Pharmaceutical Materials from South Africa Now in Clinical Use In Europe and USA by
Hemispherx Biopharma, Inc.
PR Newswire, Monday, June 01, 1998 at 10:25
PHILADELPHIA, June 1 /PRNewswire/ -- Hemispherx Biopharma, Inc.
(AMEX:HEB) announced today that pharmaceutical raw materials from Bioclones
(PTY) Ltd., Johannesburg, Republic of South Africa have been introduced
successfully into its Ampligen(R) drug product being utilized in various
clinical trials in the USA and in Europe.
The South African materials now are incorporated in some U.S.
manufacturing "runs" of Ampligen(R), a ribonucleic (RNA) compound being
developed by Hemispherx Biopharma for therapeutic use in various viral
infections of man.
Ampligen(R) is being used in eight clinical sites in the USA under a
treatment protocol approved by the FDA -- and also in Belgium to treat Chronic
Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), a severely debilitating
disease which afflicts at least 400,000 Americans. Ampligen(R) is the only
drug being developed world-wide at the Phase III level for CFS/ME.
Formerly relying on raw materials provided by Pharmacia/Upjohn, a
strategic manufacturing partner of HEB, Bioclones now is a second approved
supplier of the drug raw materials.
William A. Carter, M.D., F.A.C.P., Chairman and CEO of Hemispherx
Biopharma, stated that: "We are very pleased to welcome Bioclones as an
approved supplier. This provides additional assurances to all current
patients that their needs will be met in a timely manner. It also assures
rapid expansion of supplies to meet our growing global drug requirements."
RNA is a group of naturally occurring molecules that can increase cellular
defenses against viral diseases. HEB has obtained more than 300 patents in
this therapeutic area.
Information contained in this news release other than historical
information, should be considered forward-looking and is subject to various
risk factors and uncertainties. For instance, the strategies and operations
of HEMISPHERX involve risks of competition, changing market conditions,
changes in laws and regulations affecting these industries and numerous other
factors discussed in this release and in the Company's filings with the
Securities and Exchange Commission. Accordingly, actual results may differ
materially from those in any forward looking statements.
SOURCE Hemispherx Biopharma, Inc.
-0- 06/01/98
/CONTACT: William A. Carter, M.D., CEO & Chairman, 215-988-0080, or
Sharon Wills, Investor Relations, 212-572-0762, or fax, 212-572-0764, both of
Hemispherx Biopharma/
/Web site: hemispherx.com
|
